Literature DB >> 17635758

Revascularization for post-transplant renal artery stenosis.

Kai Ming Chow1, Cheuk Chun Szeto, Paul Sing Fun Lee, Simon Sze Ming Ho, Chi Bon Leung, Philip Kam-Tao Li.   

Abstract

BACKGROUND: Percutaneous transluminal angioplasty has now been increasingly accepted as a primary treatment option for transplant renal artery stenosis.
METHODS: This single-centre study evaluated the treatment effect of percutaneous transluminal angioplasty as primary intervention among 18 consecutive patients with angiographically demonstrated transplant renal artery stenosis.
RESULTS: Patients (14 men and 4 women, mean age 49 +/- 9 years) were followed up for a mean duration of 21.6 months after procedure. Highly significant improvement was noted in the mean arterial pressure (from baseline 105.9 +/- 10.4 mmHg to 98.6 +/- 10.0 mmHg, P < 0.001), systolic blood pressure (148.5 mmHg to 137.1 mmHg, P = 0.002) and diastolic blood pressure (85.3 mmHg to 79.4 mmHg, P = 0.002). Estimated glomerular filtration rate before and 6 months after intervention was 41.4 +/- 16.8 mL/min per 1.73 m(2) and 42.0 +/- 16.2 mL/min per 1.73 m(2), respectively (P = 0.82).
CONCLUSION: These findings show that percutaneous transluminal angioplasty in transplant renal artery stenosis appears to have a significant beneficial effect on hypertension but less impact on the improvement in renal function.

Entities:  

Mesh:

Year:  2007        PMID: 17635758     DOI: 10.1111/j.1440-1797.2007.00801.x

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  1 in total

1.  Long-term outcome of percutaneous transluminal renal angioplasty (PTRA) versus PTRA with stenting (PTRAS) in transplant renal artery stenosis.

Authors:  Nattawut Wongpraparut; Thunyarat Chaipruckmalakarn; Thongtum Tongdee; Archan Jaspttananon; Attapong Vongwiwatana; Nalinee Premasathian; Kawin Anusonadisai; Rungtiwa Pongakasira
Journal:  BMC Cardiovasc Disord       Date:  2021-04-26       Impact factor: 2.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.